Anebulo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021
Selling, General & Admin	6.18	3.87	1.34
Research & Development	5.6	2.96	2.27
Operating Expenses	11.78	6.83	3.61
Operating Income	-11.78	-6.83	-3.61
Interest Expense / Income	0	0	0.01
Other Expense / Income	-0.05	-0.01	26.63
Pretax Income	-11.73	-6.83	-30.25
Net Income	-11.73	-6.83	-30.25
Preferred Dividends	0	0	8.21
Net Income Common	-11.73	-6.83	-38.46
Shares Outstanding (Basic)	25	23	14
Shares Outstanding (Diluted)	25	23	14
Shares Change	7.41%	71.49%	-
EPS (Basic)	-0.47	-0.29	-2.83
EPS (Diluted)	-0.47	-0.29	-2.83
Free Cash Flow	-9.68	-5.44	-4.87
Free Cash Flow Per Share	-0.39	-0.23	-0.36
EBITDA	-11.73	-6.83	-30.24
EBIT	-11.73	-6.83	-30.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).